Imitrodast sodium is an inhibitor of thromboxane synthase. Imitrodast sodium can be used in the research of bronchoconstriction.

L-161638 is a potent, selective and orally active AT2 receptor antagonist. L-161638 can be used for the research of cardiovascular disease, such as hypertension.

MDA-19 N-(5-hydroxyhexyl) is a cannabinoid receptor modulator targeting CB1R/CB2R. MDA-19 N-(5-hydroxyhexyl) is used to study neurological diseases, cancer, and pain regulation.

UCSF34 (Compound 54) is a Haloperidol analogue. UCSF34 binds to the human D2L receptor, with an estimated pKi of 7.49. UCSF34 can be used in the research of schizophrenia.

S-0509 is a selective CCKB/gastrin receptor antagonist. S-0509 has a strong anti-secretion effect. S-0509 helps prevent the occurrence of duodenal ulcers.

Mivazerol is a selective α2-adrenoceptor agonist. Mivazerol has an anti-ischemic activity. Mivazerol decreases the spontaneous release of serotonin (5-HT) and significantly inhibits the immobilization stress-induced enhancement of norepinephrine (NE), dopamine (DA) and dihydroxyphenylacetic acid (DOPAC). Mivazerol can be used for myocardial ischemia research.

LY377604 hydrochloride is a human β3-adrenergic receptor agonist with an EC50 of 2.4 nM and also a β1- and β2-adrenergic receptor antagonist.

LY334370 fumarate is the fumarate of LY334370). LY334370 is a selective 5-HT1F receptor agonist with a Ki of 1.6 nM.

IHCH-7179 is a 5-HT receptor modulator. IHCH-7179 can antagonize 5-HT2A receptor and activate 5-HT1A receptor. IHCH-7179 can be used for the research of neurological disease.

MP1202 is a dual-functional agonist of MOR and KOR with EC50s of 0.32 and 0.13  μM for mMOR-1 and mKOR-1, respectively. MP1202 has functional selectivity with reduction of β-arrestin1/2 recruitment but significant activation of G-protein and Gα-subtype at hMOR and hKOR. MP1202 has potent antinociceptive effects without typical opioid side effects, but it shows conditioned place preference and aversion behaviors in subtype-selective opioid KO mice model, promising for analgesia research.

Y-20811 (sodium) is a selective and orally active thromboxane synthetase inhibitor. Y-20811 (sodium) can irreversibly inhibit thromboxane (TX) A2 synthesis. Y-20811 (sodium) can be used for the research of cardiovascular disease, such as thrombosis.

SLV-317 (free base) is an antagonist of the neurokinin-1 receptor with oral activity. SLV-317 (free base) can effective antagonist of substance P-induced effects.

KC-764 is an orally active, reversible cyclooxygenase inhibitor with relative selectivity for platelet cyclooxygenase. KC-764 inhibits platelet thromboxane A2 (TXA2) production and platelet aggregation, with IC50s of 0.23 μM and 26 nM, respectively. KC-764 can be used for the research on antiplatelet and recurrence prevention in ischemic stroke.

BMS 183920 is a diacidic and potent angiotensin II receptor antagonist, with a Ki value of 2.9 nM in the rat adrenal cortex binding assay and a KB value of 0.061 nM in the rabbit aorta functional assay. BMS 183920 can be used for research of antihypertensive.

Y-20024 (hydrochloride) is an orally active D2 receptor antagonist with blood-brain barrier permeability. Y-20024 can inhibit Apomorphine-induced ADHD in mice. Y-20024 can inhibit Apomorphine-induced vomiting in dogs. Y-20024 has prolactin-promoting activity. Y-20024 can be used in research on neurological disorders such as ADHD and vomiting.

BRI-12349 (Compound 50) is a dual antagonist of CysLT1R/CysLT2R with Ki values of 1.03 and 6.46 μM. BRI-12349 can inhibit the generation of IP1 induced by LTD4 (the main ligand of CysLTs). BRI-12349 can be used for the research of immunology and inflammation, such as asthma.

MLS6357 is a D3 dopamine receptor (D3R)-selective positive allosteric modulator (PAM)-antagonist. MLS6357 exhibits antagonist activity in the D3R-mediated and the BRET-based β-arrestin recruitment assay with IC50s of 13 and 14 μM, and no activity for other DAR subtypes (D1R/D2R/D4R/D5R) (IC50 > 100 μM). MLS6357 is also an antagonist in the D3R-mediated Go-BRET assay with an IC50 of 17 μM. MLS6357 can be used for the study of neuropsychiatric disorders, including substance use disorder.

(Rac)-MK 0686 is the racemate of MK 0686. MK 0686 is a bradykinin B1 receptor antagonist.

LMD-584 is an agonist of CCR8. LMD-584 is also an analog of LMD-009.

1192U90 is an antipsychotic agent, dopamine D2 receptor antagonist as well as serotonin 5-HT1a receptor agonist. 1192U90 reduces the number of spontaneously firing neurons in the limbic dopamine system.

DuP-532 is an angiotensin type 1 receptor antagonist with potential activity in the suppression of hypertension and heart failure. DuP-532 can react with a range of aryl and heteroaryl halides to form perfluoroalkyl(hetero)arenes in moderate to high yields. Computational studies of DuP-532 suggest that coordination of a second phenyl ring ligand may lower the energy barrier for decarboxylation of perfluorocarboxylates, thereby promoting the perfluoroalkylation reaction.

Carpipramine is an antipsychotic agent that belongs to the iminodibenzyl class. Carpipramine is a potent dopamine antagonist which blocks alpha 1- and alpha 2-adrenoceptors. Carpipramine also has antagonist properties with respect to serotonin (5-ΗΤ2) receptors. Carpipramine exhibits antipsychotic and anti-depressant effects. Carpipramine can be used for the research of neurological disease, such as post-traumatic stress disorder (PTSD) and depression.

UTPU (trisodium) (Compound 19) is a selective P2Y6R agonist with an EC50 of 0.4 μM. UTPU (trisodium) can activate the intracellular calcium signaling pathway mediated by P2Y6. UTPU (trisodium) can be used for the research of inflammation.

GYKI 12743 is a vasoselective, postsynaptic α-adrenoceptor blocker. GYKI 12743 inhibits but does not completely eliminate the cutaneous microcirculatory blood flow reduction evoked by electrical stimulation of the peripheral stump of the cut saphenous nerve in rats. GYKI 12743 can be used for the study of neurological diseases.

Tropapride is a dopamine D2 receptor antagonist. Tropapride can be used for the research of neurological disease.

EXP-6803 is a specific nonpeptide angiotensin II receptor antagonist with antihypertensive activity. EXP-6803 inhibits the contractile response to angiotensin II with a pA2 value of 7.20. EXP-6803 effectively blocks responses to angiotensin I and II while not affecting responses to bradykinin or acetylcholine in guinea pig ileum. EXP-6803 can be used for hypertension research.

ISAM-CG557 is a selective CB2R agonist, with a Ki of 54.6 nM. ISAM-CG557 reduces intracellular ROS levels and caspase activity. ISAM-CG557 exhibits significant MAPK bias and moderate G-protein bias, with CB2R EC50s of 0.60 nM (cAMP), 60.9 nM (β-arrestin) and 0.03 nM (MAPK). ISAM-CG557 exerts potent anti-inflammatory effects by reducing pro-inflammatory cytokines and increasing anti-inflammatory cytokines in cells. ISAM-CG557 can be used for the study of neuroinflammatory and neurodegenerative disorders.

MGS0008 is an orally active and brain-penetrant metabotropic glutamate receptor 2/3 (mGlu2/3) agonist. MGS0008 is promising for research of central nervous system disorders, including schizophrenia, anxiety, and neurodegenerative diseases.

Rp-dUTPαS (tetrasodium) is an isomer of the sulfur-containing nucleoride dUTP-α-S and an agonist of the purinergic P2Y2 receptor. Rp-dUTPαS (tetrasodium) selectively induces inositol phosphate accumulation in P2Y2-expressing 1321N1 cells with an EC50 of 12.5 μM.

20:4 Lyso PI is a selective G protein-coupled receptor GPR55 agonist. 20:4 Lyso PI triggers cell rounding in GPR55-expressing HEK293 cells, with an EC50 value of 10 nM. 20:4 Lyso PI promotes RhoA activation and subsequent ROCK-dependent cytoskeletal rearrangement. 20:4 Lyso PI activates the ERK signaling pathway and elevates intracellular free calcium. 20:4 Lyso PI can be used for the study of immune diseases.